New Biovanta Study Shows Best Efficacy for Common Cold
The common cold carries a substantial economic burden, causing approximately $40 billion in annual productivity losses. A recent study...
Jon Napitupulu
Rallybio Confirmatory Study Launch in Q2 2025
Rallybio Corporation announced new biomarker analyses and manufacturing process enhancements for RLYB116, its investigational once-weekly, subcutaneous C5 inhibitor for...
Daiichi Sankyo Oncology Progress at ESMO Asia, SABCS & ASH
Daiichi Sankyo will present over 45 abstracts showcasing new clinical research across its oncology portfolio at the 2024 ESMO...
Zorevunersen Data for Dravet Syndrome at AES 2024
Stoke Therapeutics, a biotechnology company focused on RNA medicine, will present data at the 2024 American Epilepsy Society (AES)...
SUDO-550: Sudo Biosciences Doses First Participants in Phase 1 Trial of Brain-Penetrant Alloste
Sudo Biosciences, a company focused on developing precision TYK2 inhibitors, has initiated a Phase 1 clinical trial for SUDO-550....
Stem Cell Market Growth, Challenges, and Opportunities to 2028
The global induced pluripotent stem cells (iPSCs) market is poised for significant growth, projected to increase from $3.4 billion...
Rlyb212 Dosing in Pregnant Women: Target-Mediated Drug Disposition
Rallybio Corporation published a manuscript detailing a novel model for determining drug dosage in pregnant women, specifically for their...
ImmunoTech Announces Cash Conservation Plan
AIM ImmunoTech Inc. has launched a cash conservation plan to support its clinical trials and drug development, particularly for...
FDA Approves Rapiblyktm for Atrial Fibrillation and Flutter
The FDA has approved Rapiblyk (landiolol), an ultra-short-acting beta-blocker, for the short-term treatment of supraventricular tachycardia (SVT), including atrial...
EU Approves Tevimbra for Esophageal and Gastric Cancer
The European Commission approved BeiGene‘s tislelizumab (TEVIMBRA), combined with chemotherapy, for first-line treatment of esophageal squamous cell carcinoma (ESCC)...